More than 31,000 people attended the annual Society for Neuroscience meeting in Washington, D.C., November 15 to 19. Twenty-five symposia, 26 minisymposia, 101 nanosymposia, 667 poster sessions, and numerous lectures, workshops, and satellite events attracted researchers engaged in all manners of neuroscience. If you failed to soak it all in, or if you opted for the relative calm of the lab this year, then check out Alzforum's conference series.
Basic preclinical discoveries keep meeting vibrant for neurodegenerative disease researchers from around the world
A micro-immunoelectrode allows researchers measure Aβ levels in the interstitial fluid of mice every 30 seconds.
Protein touted as a peripheral monocyte receptor that worsens amyloid plaque pathology in transgenic mice.
After lighting up microglia in mouse models of AD, a tracer is headed for clinical trials.
Tiny secreted vesicles emerge as important players in communication between brain cells. Are they important in neurodegeneration?
A new trend in cell biology points to vesicles released from cells as agents that form and spread pathogenic proteins.
Lipoprotein cap on pigment cell exosomes is essential for production of an amyloid scaffold that concentrates melanin.
Using creative ways of mining genetic data, researchers are coming up with new risk variants for Alzheimer’s.
Small molecules headed for clinical trials target the cell surface protein, displace bound Aβ, and rescue memory in animal models of Alzheimer's.
Scientists are finding how calcium dysregulation in mouse models of Alzheimer’s shrivels synapses and impairs neural plasticity, with effects that extend to the network level.
In mouse models of AD, one astrocyte purinergic receptor makes glia hyperactive, while another may suppress memory. Both are upregulated in the AD brain, researchers report.
Tiny spheres full of oxygen soothe neuroinflammation and fight neurodegeneration, researchers reported at SfN. The concept may seem strange, but AD trials are on the horizon.